Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.
Identifieur interne : 000A40 ( Main/Exploration ); précédent : 000A39; suivant : 000A41Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.
Auteurs : Susan K. Bowles [Canada] ; Wayne Lee ; Andrew E. Simor ; Mary Vearncombe ; Mark Loeb ; Susan Tamblyn ; Margaret Fearon ; Yan Li ; Allison McgeerSource :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2002.
Descripteurs français
- KwdFr :
- Acétamides (effets indésirables), Acétamides (usage thérapeutique), Adulte d'âge moyen (MeSH), Amantadine (usage thérapeutique), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains (MeSH), Maisons de repos (MeSH), Mâle (MeSH), Ontario (épidémiologie), Oséltamivir (MeSH), Résultat thérapeutique (MeSH), Soins de longue durée (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (administration et posologie), Épidémies de maladies (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Acétamides, Antiviraux.
- prévention et contrôle : Grippe humaine.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acétamides, Amantadine, Antiviraux.
- épidémiologie : Grippe humaine, Ontario.
- Adulte d'âge moyen, Femelle, Humains, Maisons de repos, Mâle, Oséltamivir, Résultat thérapeutique, Soins de longue durée, Sujet âgé, Sujet âgé de 80 ans ou plus, Épidémies de maladies.
English descriptors
- KwdEn :
- Acetamides (adverse effects), Acetamides (therapeutic use), Aged (MeSH), Aged, 80 and over (MeSH), Amantadine (therapeutic use), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Disease Outbreaks (MeSH), Female (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Long-Term Care (MeSH), Male (MeSH), Middle Aged (MeSH), Nursing Homes (MeSH), Ontario (epidemiology), Oseltamivir (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Acetamides, Antiviral Agents.
- chemical , therapeutic use : Acetamides, Amantadine, Antiviral Agents.
- geographic , epidemiology : Ontario.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Disease Outbreaks, Female, Humans, Long-Term Care, Male, Middle Aged, Nursing Homes, Oseltamivir, Treatment Outcome.
Abstract
OBJECTIVES
To describe the experience of Ontario long-term care facilities that used oseltamivir during influenza outbreaks in 1999/2000.
DESIGN
Case series.
SETTING
Ten Ontario long-term care facilities for older people and their residents.
PARTICIPANTS
Older residents of long-term care facilities.
INTERVENTION
Oseltamivir for treatment or prophylaxis during 11 influenza outbreaks in 1999/2000.
MEASUREMENTS
Control of outbreaks; pneumonia, hospitalization, and death complicating acute influenza.
RESULTS
All outbreaks were due to influenza A//H3N2/Sydney/05/97. One facility elected to use oseltamivir for treatment and amantadine for prophylaxis. The remaining nine facilities (10 outbreaks) recommended oseltamivir for treatment and prophylaxis (after amantadine failure in five and as primary prophylaxis in five). Use of oseltamivir was associated with termination of the outbreak in all eight evaluable outbreaks. Overall, 178/185 (96%) case-residents met the case definition of influenza and had complete data for evaluation. Of these, 63 (35%) were treated with antibiotics, 37 (21%) were diagnosed with pneumonia, 19 (11%) were hospitalized, and 16 (9%) died. Compared with residents receiving no therapy or who became ill while taking amantadine, residents who received oseltamivir within 48 hours of the onset of symptoms were less likely to be prescribed antibiotics, to be hospitalized, or to die (P <.05 for each outcome). These differences persisted and remained statistically significant when corrected for influenza immunization status. A total of 730 residents received oseltamivir prophylaxis for a median of 9 days (range 5-12). Of these, side effects were identified in 30 (4.1%), the most common being diarrhea (12 residents, 1.6%), cough (5, 0.7%), confusion (4, 0.5%) and nausea (4, 0.5%).
CONCLUSIONS
Oseltamivir is safe and appears to be effective when used as treatment or prophylaxis to control outbreaks of influenza in older nursing home residents.
DOI: 10.1046/j.1532-5415.2002.50153.x
PubMed: 11982659
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.</title><author><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario.</nlm:affiliation><country>Canada</country><placeName><region type="province">Ontario</region></placeName><wicri:cityArea>Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Wayne" sort="Lee, Wayne" uniqKey="Lee W" first="Wayne" last="Lee">Wayne Lee</name></author><author><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name></author><author><name sortKey="Vearncombe, Mary" sort="Vearncombe, Mary" uniqKey="Vearncombe M" first="Mary" last="Vearncombe">Mary Vearncombe</name></author><author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name></author><author><name sortKey="Tamblyn, Susan" sort="Tamblyn, Susan" uniqKey="Tamblyn S" first="Susan" last="Tamblyn">Susan Tamblyn</name></author><author><name sortKey="Fearon, Margaret" sort="Fearon, Margaret" uniqKey="Fearon M" first="Margaret" last="Fearon">Margaret Fearon</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11982659</idno><idno type="pmid">11982659</idno><idno type="doi">10.1046/j.1532-5415.2002.50153.x</idno><idno type="wicri:Area/Main/Corpus">000A59</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A59</idno><idno type="wicri:Area/Main/Curation">000A59</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A59</idno><idno type="wicri:Area/Main/Exploration">000A59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.</title><author><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario.</nlm:affiliation><country>Canada</country><placeName><region type="province">Ontario</region></placeName><wicri:cityArea>Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Wayne" sort="Lee, Wayne" uniqKey="Lee W" first="Wayne" last="Lee">Wayne Lee</name></author><author><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name></author><author><name sortKey="Vearncombe, Mary" sort="Vearncombe, Mary" uniqKey="Vearncombe M" first="Mary" last="Vearncombe">Mary Vearncombe</name></author><author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name></author><author><name sortKey="Tamblyn, Susan" sort="Tamblyn, Susan" uniqKey="Tamblyn S" first="Susan" last="Tamblyn">Susan Tamblyn</name></author><author><name sortKey="Fearon, Margaret" sort="Fearon, Margaret" uniqKey="Fearon M" first="Margaret" last="Fearon">Margaret Fearon</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name></author></analytic><series><title level="j">Journal of the American Geriatrics Society</title><idno type="ISSN">0002-8614</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (adverse effects)</term><term>Acetamides (therapeutic use)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Amantadine (therapeutic use)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Disease Outbreaks (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Long-Term Care (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Nursing Homes (MeSH)</term><term>Ontario (epidemiology)</term><term>Oseltamivir (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (effets indésirables)</term><term>Acétamides (usage thérapeutique)</term><term>Adulte d'âge moyen (MeSH)</term><term>Amantadine (usage thérapeutique)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Maisons de repos (MeSH)</term><term>Mâle (MeSH)</term><term>Ontario (épidémiologie)</term><term>Oséltamivir (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Soins de longue durée (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Épidémies de maladies (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Amantadine</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ontario</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acétamides</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term><term>Amantadine</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Ontario</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Disease Outbreaks</term><term>Female</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Nursing Homes</term><term>Oseltamivir</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Maisons de repos</term><term>Mâle</term><term>Oséltamivir</term><term>Résultat thérapeutique</term><term>Soins de longue durée</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Épidémies de maladies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To describe the experience of Ontario long-term care facilities that used oseltamivir during influenza outbreaks in 1999/2000.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Case series.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>Ten Ontario long-term care facilities for older people and their residents.</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>Older residents of long-term care facilities.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTION</b></p><p>Oseltamivir for treatment or prophylaxis during 11 influenza outbreaks in 1999/2000.</p></div><div type="abstract" xml:lang="en"><p><b>MEASUREMENTS</b></p><p>Control of outbreaks; pneumonia, hospitalization, and death complicating acute influenza.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>All outbreaks were due to influenza A//H3N2/Sydney/05/97. One facility elected to use oseltamivir for treatment and amantadine for prophylaxis. The remaining nine facilities (10 outbreaks) recommended oseltamivir for treatment and prophylaxis (after amantadine failure in five and as primary prophylaxis in five). Use of oseltamivir was associated with termination of the outbreak in all eight evaluable outbreaks. Overall, 178/185 (96%) case-residents met the case definition of influenza and had complete data for evaluation. Of these, 63 (35%) were treated with antibiotics, 37 (21%) were diagnosed with pneumonia, 19 (11%) were hospitalized, and 16 (9%) died. Compared with residents receiving no therapy or who became ill while taking amantadine, residents who received oseltamivir within 48 hours of the onset of symptoms were less likely to be prescribed antibiotics, to be hospitalized, or to die (P <.05 for each outcome). These differences persisted and remained statistically significant when corrected for influenza immunization status. A total of 730 residents received oseltamivir prophylaxis for a median of 9 days (range 5-12). Of these, side effects were identified in 30 (4.1%), the most common being diarrhea (12 residents, 1.6%), cough (5, 0.7%), confusion (4, 0.5%) and nausea (4, 0.5%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Oseltamivir is safe and appears to be effective when used as treatment or prophylaxis to control outbreaks of influenza in older nursing home residents.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11982659</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.</ArticleTitle><Pagination><MedlinePgn>608-16</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe the experience of Ontario long-term care facilities that used oseltamivir during influenza outbreaks in 1999/2000.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Case series.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Ten Ontario long-term care facilities for older people and their residents.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Older residents of long-term care facilities.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Oseltamivir for treatment or prophylaxis during 11 influenza outbreaks in 1999/2000.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Control of outbreaks; pneumonia, hospitalization, and death complicating acute influenza.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All outbreaks were due to influenza A//H3N2/Sydney/05/97. One facility elected to use oseltamivir for treatment and amantadine for prophylaxis. The remaining nine facilities (10 outbreaks) recommended oseltamivir for treatment and prophylaxis (after amantadine failure in five and as primary prophylaxis in five). Use of oseltamivir was associated with termination of the outbreak in all eight evaluable outbreaks. Overall, 178/185 (96%) case-residents met the case definition of influenza and had complete data for evaluation. Of these, 63 (35%) were treated with antibiotics, 37 (21%) were diagnosed with pneumonia, 19 (11%) were hospitalized, and 16 (9%) died. Compared with residents receiving no therapy or who became ill while taking amantadine, residents who received oseltamivir within 48 hours of the onset of symptoms were less likely to be prescribed antibiotics, to be hospitalized, or to die (P <.05 for each outcome). These differences persisted and remained statistically significant when corrected for influenza immunization status. A total of 730 residents received oseltamivir prophylaxis for a median of 9 days (range 5-12). Of these, side effects were identified in 30 (4.1%), the most common being diarrhea (12 residents, 1.6%), cough (5, 0.7%), confusion (4, 0.5%) and nausea (4, 0.5%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Oseltamivir is safe and appears to be effective when used as treatment or prophylaxis to control outbreaks of influenza in older nursing home residents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Simor</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Vearncombe</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Loeb</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tamblyn</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fearon</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><CollectiveName>Oseltamivir Compassionate Use Program Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11982659</ArticleId><ArticleId IdType="pii">50153</ArticleId><ArticleId IdType="doi">10.1046/j.1532-5415.2002.50153.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region></list><tree><noCountry><name sortKey="Fearon, Margaret" sort="Fearon, Margaret" uniqKey="Fearon M" first="Margaret" last="Fearon">Margaret Fearon</name><name sortKey="Lee, Wayne" sort="Lee, Wayne" uniqKey="Lee W" first="Wayne" last="Lee">Wayne Lee</name><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name><name sortKey="Tamblyn, Susan" sort="Tamblyn, Susan" uniqKey="Tamblyn S" first="Susan" last="Tamblyn">Susan Tamblyn</name><name sortKey="Vearncombe, Mary" sort="Vearncombe, Mary" uniqKey="Vearncombe M" first="Mary" last="Vearncombe">Mary Vearncombe</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11982659
|texte= Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11982659" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |